All Type of News
Stronger patent rights and massive drug price cuts set to corner local drug makers
After four years of circular debate, political feuds and a last-minute tear gas attack, the free trade pact between Korea and the United States is finally set to take effect. The parliamentary passage of the deal brin...
KPMA threatens to boycott drug production
The Korea Pharmaceutical Manufacturers Association said Wednesday that it will consider stopping all manufacturing once the price-reduction policy comes into effect.
“We will also take legal steps against it,” sai...
Handling of health and medical bills hit sang
The main opposition Democratic Party (DP) vowed Wednesday to boycott all parliamentary sessions in protest at the ruling party's unilateral passage of the disputed free trade agreement with the U.S.
The DP and othe...
Korea-U.S. FTA opens new doors for U.S. pharmaceutical firms
The Korea-U.S. Free Trade Agreement (KORUS FTA) was finally approved by Korea’s National Assembly on Tuesday after years on the backburner.
The initial negotiations were concluded on April 2, 2007 and the accord w...
Impact of KORUS FTA on pharmaceutical industry
The just-ratified Korea-U.S. Free Trade Agreement (KORUS FTA) will have a different impact across industries based on the final tariff agreement.
The auto and textile industry export competitiveness to the U.S. wi...
Trade deal corners local drug makers
Domestic drug makers should focus on research and development of new drugs to survive in an era of the Korea-U.S. FTA, experts said.
They should pursue the knowledge-intensive industry based on research and develop...
Government to support drug development to counter FTA
The government plans to increase its spending on the development of new drugs, as part of follow-up measures to the free trade agreement (FTA) ratified with the United States.
To this end, three governmental agenci...
Pharmaceutical firms seeking to improve financial soundness
Korea’s pharmaceutical companies are seeking to set up a stabilization scheme to cope with the government’s massive drug price cuts starting next April, including pre-emptive measures to seek future stability.
The ...
Green Cross tops in per capita sales
Green Cross Corp. ranked the highest in per capita sales of 428 million won among 31 listed pharmaceutical companies during a January-September period of this year on the back of robust business performance, according...
Debate on new outlets of OTC medicines
After the lawmakers of the National Assembly’s Health and Welfare Committee from the ruling and opposition camps decided not to put a bill to vote to make cold medicines and fever reducers available at supermarkets an...
